RESUMO
Curettage of benign bone tumor is a common cause for bone defect. For such bone defect repair, autogenous bone, allogeneic bone and traditional artificial bone graft substitutes have many disadvantages. In recent years, a biomimetic mineralized collagen (MC) with similar composition and microstructures to the natural bone matrix was developed and used for treating various bone defects. In this work, a retrospective study analyzed clinical outcomes of patients treated with curettage of benign bone tumors and bone grafting with MC, in comparison to another group treated with the same surgical method and autogenous bone. Lane-Sandhu X-ray score of the autogenous bone group was superior to the MC group at 1 month after the operation, but the two groups had no statistical difference at 6 and 12 months. The MC group was better in Musculoskeletal Tumor Society scoring at 1 and 6 months after the operation, and the two groups had no statistical difference at 12 month. Therefore, the MC performed not as good as autogenous bone in early stage of bone healing but achieved comparable outcomes in long-term follow-ups. Moreover, the MC has advantages in function recovery and avoided potential complications induced by harvesting autogenous bone.
RESUMO
A retrospective study of consecutive patients.The purpose of this study was to compare the clinical effect of biomimetic mineralized collagen (MC) modified polymethylmethacrylate (PMMA) bone cement and traditional PMMA bone cement for the treatment of osteoporotic vertebral compression fractures (OVCF).New fracture on adjacent level is the major postoperative complication of percutaneous vertebroplasty (PVP). The clinical incidence was 12.4% to 27.7%. The increased stiffness of the treated vertebral body caused by filling bone cement is considered as one of the main reasons.A total of 30 patients treated with traditional PMMA bone cement from June 2013 to March 2016 were selected as the traditional group, while 50 patients treated with MC modified PMMA bone cement from July 2014 to March 2016 were selected as the modified group. The 2 groups were compared by injection time of the bone cements, postoperative pain relief effects, vertebral height restoration, CT value changes of the treated vertebral bodies, and postoperative complications in the clinical observations.The surgeries were successfully completed in both groups. In the treatment of OVCF, the MC modified bone cement was able to achieve the same pain relief and vertebral height restoration effects compared to traditional bone cement during the follow-ups, although the injection time of the cement was prolonged in the operation. MC modified bone cement significantly reduced the incidence of postoperative adjacent vertebral fracture from 13.3% to 2%, and significantly increased bone density of the treated vertebral bodies.The MC modified PMMA bone cement showed good clinical outcomes and better mechanical properties than the traditional bone cements.
Assuntos
Cimentos Ósseos/química , Fraturas por Compressão/cirurgia , Fraturas da Coluna Vertebral/cirurgia , Vertebroplastia/métodos , Idoso , Idoso de 80 Anos ou mais , Materiais Biomiméticos , Colágeno/química , Feminino , Fraturas por Compressão/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Osteoporose/complicações , Dor Pós-Operatória/epidemiologia , Polimetil Metacrilato/química , Estudos Retrospectivos , Fraturas da Coluna Vertebral/etiologia , Tomografia Computadorizada por Raios XRESUMO
In the present study, water-soluble chitosan (WSC) was prepared by hydrolysis of chitosan with commercial α-amylase, and the effect of WSC on osteoblast function, i.e. alkaline phosphatase activity (ALP), cell viability, mineralization, and reactive oxygen species (ROS) in osteoblastic MC3T3-E1 cells was investigated. Osteoblastic MC3T3-E1 cells were cultured in various concentrations of WSC solutions (1-5 mg/mL) for designated time and then the ALP, cell viability, mineralization, and ROS in the cells were evaluated. Treatments of osteoblastic with WSC caused a significant increase in ALP, cell viability, and mineralization in osteoblastic MC3T3-E1 cells. Moreover, treatments of osteoblastic with WSC decreased ROS level in osteoblastic MC3T3-E1 cells. The results demonstrate that the WSC may reduce or prevent osteoblasts degeneration through antioxidant activity.